Published in AIDS Weekly, June 23rd, 2008
"Fifty-six HIV+ patients receiving lopinavir/ritonavir (LPV/r) (group I=24 controls; II=23 HIV/HCV-coinfected; III=9 cirrhotic HIV/HCV-coinfected) were included.Total (n=56) and unbound (n=36) LPV pharmacokinetic parameters...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.